3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluorocytidine
CAS: 134790-39-9
Ref. 3D-ND08303
2g | 136.00 € | ||
5g | 192.00 € | ||
10g | 271.00 € | ||
25g | 406.00 € | ||
50g | 543.00 € |
Product Information
- 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidineGemcitabine3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluoro-D-cytidine3',5'-Di-O-benzoyl -2',2'-difluoro-2'-deoxycytidine
- 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidine
- 2',2'-Difluoro-3',5'-dibenzoyl-2'-deoxycytidine (beta isomer)
- 2'-deoxy-2',2'-difluoro-3',5'-bis-O-(phenylcarbonyl)cytidine
- 2,2-Difluoro-2-Deoxycytidine-3,5-Dibenzoate
- 3',5'-Di-O-benzoyl-2',2'-difluoro-2'-deoxy cytidine
- 3′,5′-Di-O-benzoyl-2′-deoxy-2′,2′-difluorocytidine
- Cytidine, 2′-deoxy-2′,2′-difluoro-, 3′,5′-dibenzoate
- T9
- T9:2’,2’-Difluoro-2’-deoxycytidine-3’,5’-dibenzoate
- See more synonyms
Folfirinox is a nucleoside analog that is structurally related to gemcitabine. It is metabolized by the enzyme equilibrative nucleoside transporter (ENT) to form 2'-deoxy-2',2'-difluorocytidine (DFD), which is incorporated into DNA by polymerase chain reaction. Folfirinox has been shown to have antitumor immunity and immunomodulatory effects in mice and humans, and it also has the potential to be used as a radiosensitizer for squamous cell carcinomas. Folfirinox has been found to be effective against pancreatic cancer cells in vitro and in vivo, with a median survival time of 36 days for mice treated with low doses of the drug.
Chemical properties
Technical inquiry about: 3D-ND08303 3',5'-Di-O-benzoyl-2'-deoxy-2',2'-difluorocytidine
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.